TMPRSS2 and Familial prostate cancer: In prostate cancer, new loops with specific histone modifications may serve as new diagnostic markers; the TMPRSS2-ERG fusion has been used as a marker in diagnosis and risk assessment for many years, even before chromatin loops were identified as the culprit [102].